Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) announced the expansion of its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The company has added Hadassah-University Medical Center in Jerusalem as a new trial site, joining prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and IMCA.
The trial aims to evaluate safety, tolerability, and pharmacokinetics of CMND-100, while exploring its potential to reduce alcohol cravings. The expansion targets the global AUD market affecting over 280 million people, representing a multibillion-dollar opportunity given current limited treatment options.
Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, their MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine's Department of Psychiatry and Johns Hopkins University, will evaluate the drug's safety, tolerability, and pharmacokinetic profile.
The study targets individuals aged 18-60 who either report heavy binge drinking or are diagnosed with AUD. The U.S. substance use disorder treatment market, valued at $35.1 billion in 2021, is projected to reach $60.2 billion by 2029. The company aims to address limitations in current AUD treatments, which have shown limited effectiveness and adverse side effects.
Clearmind Medicine (Nasdaq: CMND) has partnered with a leading government affairs consulting firm to advance psychedelic-based treatments in the healthcare sector. The collaboration aims to navigate regulatory landscapes and promote acceptance of psychedelic therapeutics among U.S. policymakers.
The company's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for Alcohol Use Disorder (AUD) at Yale School of Medicine and Johns Hopkins University. The partnership focuses on educating policymakers about psychedelics' therapeutic potential, particularly for treating conditions like PTSD and mental health disorders, while supporting the development of science-based regulatory frameworks.
Clearmind Medicine Inc. (NASDAQ: CMND) announces a live webinar titled "Gazing Through the Crystal Ball" scheduled for May 21, 2025, at 12:00 PM ET. The event will feature prominent experts in psychedelic science discussing the evolving landscape of the industry amid changing FDA policies and political climates.
The distinguished panel includes Rick Doblin, Founder and President of MAPS, Robin Carhart-Harris, neuropharmacologist at UCSF, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine leading the development of CMND-100 for Alcohol Use Disorder, and Mark Haden, VP Business Development at Clearmind. The discussion will be moderated by Shannon Smadella, a social entrepreneur and former MAPS Canada board member.
Clearmind Medicine (NASDAQ: CMND) has announced the publication of a European patent (EP 4531826) for its psychedelic-based combination therapy targeting cocaine addiction. The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Preclinical trials conducted at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their response to natural rewards like sucrose. This suggests the treatment specifically targets drug-related compulsions rather than the general reward system.
The patent publication strengthens Clearmind's intellectual property portfolio and complements similar filings in other markets. The development is part of an ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) to explore combined MEAI and PEA-based technologies for treating central nervous system disorders.
Clearmind Medicine (Nasdaq: CMND) has filed a new international patent application for treating eating disorders using a combination of 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA). The clinical-stage biotech company aims to address the complex factors associated with conditions like anorexia and bulimia.
The announcement highlights the significant global impact of eating disorders, which affect up to 70 million people worldwide. The prevalence has increased from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents. These disorders rank among the top ten leading causes of disability among young women and have one of the highest mortality rates among mental disorders.
Clearmind Medicine (NASDAQ: CMND) has completed the initiation of all planned sites for its Phase I/IIa clinical trial in Alcohol Use Disorder (AUD), including the Yale School of Medicine's Department of Psychiatry. The company has secured all necessary preparations, including FDA approval for the Investigational New Drug (IND), Institutional Review Board (IRB) approvals, and the implementation of an Electronic Data Capture (EDC) system.
The trial will be conducted at three locations: Yale School of Medicine led by Dr. Anahita Bassir Nia, Johns Hopkins University School of Medicine, and the IMCA Center in Israel. The study will evaluate CMND-100, the company's drug candidate, which has been successfully manufactured and imported into the United States. The company is now ready to begin patient enrollment for this innovative treatment targeting alcoholism.